What’s holding pharma back from true digital transformation? At NEXT Pharma 2025, Our CEO Rob Verheul and Roeland van der ...

Follow-up results from the phase 3 EMBER-3 study showed that, as a monotherapy, Inluriyo demonstrated a 38% reduction in the ...

Galderma’s Nemluvio (nemolizumab) has shown rapid relief of itch, as well as improvement in sleep, in patients with atopic ...